The Medicines Evaluation Unit has recently partnered with Arxx Therapeutics.
We happy to share that, with the help of MEU and CRO Solutions, Arxx have completed dosing of all healthy volunteers in their ongoing phase 1 study and successfully initiated the multiple ascending dose part in patients with psoriasis.
The trial is designed to establish the safety, pharmacokinetics (PK) and exploratory pharmacodynamics (PD) of AX-202; a first-in-class, anti-S100A4 monoclonal antibody in development for chronic inflammatory and fibrotic diseases.
Tel: +44 (0)161 946 4050
Email: [email protected]